Missing data in IPF trials: Do not let methodological issues undermine a major therapeutic breakthrough

European Respiratory Journal

Volumn 46, Issue 3, 2015, Pages 607-614

  Thabut, Gabriel ^a,b   Crestani, Bruno ^a,b   Porcher, Raphaël ^c,d   Richeldi, Luca ^e  

^a BICHAT HOSPITAL   (France)

^b Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^c Institut Cochin   (France)

^d PARIS DESCARTES UNIVERSITY   (France)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DATA PROCESSING; EDITORIAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG TRANSPLANTATION; MISSING DATA; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STUDY DESIGN; SURVIVAL; SYSTEMATIC ERROR; DRUG EFFECTS; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; INFORMATION PROCESSING; LUNG FUNCTION TEST; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; VITAL CAPACITY;

INDOLE DERIVATIVE; NINTEDANIB; PIRFENIDONE; PYRIDONE DERIVATIVE;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84942787214     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02204-2014     Document Type: Editorial

References (45)

1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
3. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
5. Du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186: 712-715.
6. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.
7. Karimi-Shah BA. Pulmonary-Allergy Drugs Advisory Committee Meeting. Pirfenidone capsules NDA 22-535, S-000. Silver Spring, US Food and Drug Administration, 2010.
8. Albera C. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011; 20: 195-200.
9. Thabut G, Crestani B. Treatments for idiopathic pulmonary fibrosis. N Engl J Med 2014; 371: 782.
10. Collard HR, King TE, Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
11. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
12. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
13. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
14. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
15. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
16. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
17. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
18. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
19. Seymour S. Overview of the FDA background materials for New Drug Application (NDA) 22-535, Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce the decline in lung function. Silver Spring, US Food and Drug Administration, 2010.
20. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis - FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372: 1189-1191.
21. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
22. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-2101.
23. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-162.
24. Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; 42: 1622-1632.
25. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649.
26. Crestani B, Chapron J, Wallaert B, et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J 2012; 39: 772-775.
27. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
28. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
29. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
30. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
31. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon γ-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
32. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
33. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
34. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
35. King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189: 825-831.
36. Swigris J, Fairclough D. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 695-696.
37. Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation. J Biopharm Stat 2013; 23: 1352-1371.
38. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52: 1324-1333.
39. Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat 2013; 12: 337-347.
40. Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol 2010; 28: 2796-2801.
41. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469-475.
42. King TE Jr, Noble PW, Bradford WZ. Treatments for idiopathic pulmonary fibrosis. N Engl J Med 2014; 371: 783-784.
43. Xiang F, Murray S. Restricted mean models for transplant benefit and urgency. Stat Med 2012; 31: 561-576.
44. 1-antitrypsin deficiency-related COPD. Eur Respir J 2014; 44: 78-86.
45. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2142-2143.